Loading
companiesCompany
argenx
argenx is a Belgian antibody company best known for efgartigimod in autoimmune disease; its cancer programme, the anti-CD70 antibody cusatuzumab for acute myeloid leukaemia, was returned by its partner in 2021.
Also called: argenx SEArgenx
Overview
argenx, based in Ghent with Dutch and US operations and listed on Euronext and Nasdaq, develops antibodies from its llama-derived SIMPLE Antibody platform. Its lead product efgartigimod is approved for myasthenia gravis and other autoimmune conditions. In cancer it developed cusatuzumab, an anti-CD70 antibody tested with azacitidine in acute myeloid leukaemia, which Janssen licensed in 2018 and handed back in 2021. OnCo records it as a registry sponsor of phase 3 cancer trials.
Headquarters
Ghent, BE
Scorecard
All companies#389of 1244 companies, score 9
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +4
0 approved, 0 in phase 3, 1 earlier, 1 targets, 4 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 2monoclonal antibody
Cusatuzumab is an experimental monoclonal antibody from OncoVerity in phase 2 trials for acute myeloid leukaemia, aimed at CD70.
Similar pages
cancers
fronts
drugs
Phase 2monoclonal antibody